트랄로키누맙과 두필루맙의 매칭 조정 간접 비교
Matching-adjusted Indirect Comparison (MAIC) of Tralokinumab Versus Dupilumab for the Treatment of Moderate to Severe Adult Atopic Dermatitis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Atopic dermatitis (AD) is a chronic, recurrent inflammatory skin disease. Both tralokinumab and dupilumab have been recommended in the European Guideline for the treatment of adult patients with severe AD. In Korea, dupilumab has been approved for patients with moderate to severe AD, and reimbursed for those with severe AD. Since there is no clinical trial directly comparing tralokinumab and dupilumab, we conducted indirect comparison to assess the clinical usefulness in patients with AD. Methods: We selected clinical trials for indirect comparison through a systematic literature review. Individual patient data were available for the tralokinumab clinical trial, and aggregated data were available for the dupilumab clinical trial. Therefore, we employed the Matching-Adjusted Indirect Comparison (MAIC) method. The treatment efficacy was assessed based on whether patients achieved a 75% reduction on the Eczema Area and Severity Index (EASI 75) after drug administration. Results: The difference in the proportion of patients achieving EASI 75 between tralokinumab and dupilumab was 4.7% (95% CI: −7.9 to 17.3). Considering the non-inferiority margin for the EASI 75 achievement rate is −10%, tralokinumab is deemed non-inferior to dupilumab as the lower bound of the CI for the difference in the EASI 75 achievement rate between tralokinumab and dupilumab was within −10%. Conclusion: We conducted a MAIC analysis comparing tralokinumab and dupilumab based on EASI 75 achievement. The findings of this study show that tralokinumab is non-inferior to dupilumab and can be implemented in Korean clinical settings with a therapeutic position comparable to dupilumab.
Abstract
Objective: Atopic dermatitis (AD) is a chronic, recurrent inflammatory skin disease. Both tralokinumab and dupilumab have been recommended in the European Guideline for the treatment of adult patients with severe AD. In Korea, dupilumab has been approved for patients with moderate to severe AD, and reimbursed for those with severe AD. Since there is no clinical trial directly comparing tralokinumab and dupilumab, we conducted indirect comparison to assess the clinical usefulness in patients with AD. Methods: We selected clinical trials for indirect comparison through a systematic literature review. Individual patient data were available for the tralokinumab clinical trial, and aggregated data were available for the dupilumab clinical trial. Therefore, we employed the Matching-Adjusted Indirect Comparison (MAIC) method. The treatment efficacy was assessed based on whether patients achieved a 75% reduction on the Eczema Area and Severity Index (EASI 75) after drug administration. Results: The difference in the proportion of patients achieving EASI 75 between tralokinumab and dupilumab was 4.7% (95% CI: −7.9 to 17.3). Considering the non-inferiority margin for the EASI 75 achievement rate is −10%, tralokinumab is deemed non-inferior to dupilumab as the lower bound of the CI for the difference in the EASI 75 achievement rate between tralokinumab and dupilumab was within −10%. Conclusion: We conducted a MAIC analysis comparing tralokinumab and dupilumab based on EASI 75 achievement. The findings of this study show that tralokinumab is non-inferior to dupilumab and can be implemented in Korean clinical settings with a therapeutic position comparable to dupilumab.
참고문헌 (29)
- Ceci RLF, "Goldman’s Cecil Medicine, Single Volume, 24: Goldman’s Cecil Medicine (Vol. 1)", pp.2209~2211 (2012), Elsevier Health Sciences
- "Healthcare big data system"[URL]
- Wollenberg A, "European guideline(EuroGuiDerm)on atopic eczema : part I-systemic therapy", Journal of the European Academy of Dermatology and Venereology, 36(9), pp.1409~1431 (2022)
- Bieber T, "Interleukin-13 : Targeting an underestimated cytokine in atopic dermatitis", Allergy, 75(1), pp.54~62 (2020)
- Zhang Y, "The efficacy and safety of IL-13inhibitors in atopic dermatitis : A systematic review and metaanalysis", Front Immunol, 13, pp.923362~ (2022)
- "Reimbursement criteria-Upadacitinib"[URL]
- "Rinvoq approval"[URL]
- HIRA, "Guidelines for Evaluating the Economics of Drugs", ~ (2021)
- Gutermuth J, "Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A : A placebo-controlled, randomized, phase III clinical trial(ECZTRA 7)", British Journal of Dermatology, 186(3), pp.440~452 (2022)
- de Bruin-Weller M, "Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable : a placebo-controlled, randomized phase III clinical trial(LIBERTY AD CAFÉ)", British Journal of Dermatology, 178(5), pp.1083~1101 (2018)
- Kimball AB, "Interpretation of EASI-75from a patient perspective—a post hoc analysis from a phase 2b trial of dupilumab in adults with moderate-to-severe atopic dermatitis", JAAD, 76(6 Suppl 1), pp.416~ (2017)
- Schmitt J, "The Harmonising Outcome Measures for Eczema(HOME)statement to assess clinical signs of atopic eczema in trials", J Allergy Clin Immunol, 134(4), pp.800~807 (2014)
- "Reimbursement criteria - Dupilumab"[URL]
- 김정은, "2019 Consensus Korean Diagnostic Guidelines to Define Severity Classification and Treatment Refractoriness for Atopic Dermatitis: Objective and Subjective Assessment of Severity", Annals of Dermatology, 31(6), pp.654~661 (2019), 대한피부과학회[DOI]
- Wangge G, "The challenges of determining noninferiority margins : a case study of noninferiority randomized controlled trials of novel oral anticoagulants", CMAJ, 185(3), pp.222~227 (2013)
- Halmos B, "A matching-adjusted indirect comparison of pembrolizumab+ chemotherapy vs. nivolumab+ipilimumab as first-line therapies in patients with PD-L1 TPS≥1%metastatic NSCLC", Cancers, 12(12), pp.3648~ (2020)
- Signorovitch JE, "Comparative effectiveness without head-to-head trials : a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept", Pharmacoeconomics, 28(10), pp.935~945 (2010)
- Jackson D, "Alternative weighting schemes when performing matching-adjusted indirect comparisons", Res Synth Methods, 12(3), pp.333~346 (2021)
- Signorovitch JE, "Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research", Value Health, 15(6), pp.940~947 (2012)
- "Non-Inferiority Clinical Trials to Establish Effectiveness Guidance for Industry" (2016)[URL]
- Reich K, "Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized, double-blind, multicentre phase 3trial", Lancet, 400(10348), pp.273~282 (2022)
- CADTH, "Clinical review report-Dupilumab.CADTTH Common Drug Review", Canadian Agency for Drugs and Technologies in Health, ~ (2018)
- Sedeh FB, "Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis : A Systematic Review and Meta-analysis", Acta Derm Venereol, 102 (2022)
- Silverberg JI, "Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis : a systematic literature review and network meta-analysis", Journal of the European Academy of Dermatology and Venereology, 35(9), pp.1797~1810 (2021)
- Pereyra-Rodriguez, JJ, "Short-term effectiveness and safety of biologics and small molecule drugs for moderate to severe atopic dermatitis : a systematic review and network meta-analysis", Life, 11(9), pp.927~ (2021)
- Paolino A, "Non‐biologic systemic treatments for atopic dermatitis: Current state of the art and future directions", Clinical & Experimental Allergy, 53(5), pp.495~510 (2023)
- "Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis" (2022)[URL]
- Paik PK, "Matching-Adjusted Indirect Comparison(MAIC)of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations", Adv Ther, 39, pp.3159~3179 (2022)